Adding to yesterday’s announcement of a $1.26 billion investment in Dublin, the company said it plans to match that investment to expand its Puurs, Belgium manufacturing site.
The investment to expand manufacturing at Pfizer’s plant in Dublin would double its capacity to produce key substances used in biological drugs.
Under the terms, biotech firm Roivant will be responsible for funding the development and will retain commercialization rights for RVT-3101, once approved, in the United States and Japan.
Nimbus Therapeutics reported positive Phase IIb results on Wednesday for its TYK2 inhibitor, NDI-034858, in moderate-to-severe plaque psoriasis.
Late Monday, Arvinas Inc. was forced to divulge the contents of its upcoming breast cancer data presentation, slated for the 2022 San Antonio Breast Cancer Symposium (“SABCS”). The clinical-stage biopharma was originally set to unveil the Phase II data for its lead breast cancer medication, ARV-471, on Dec. 8, 2022. But Arvinas’ and Pfizer’s joint abstract was inadvertently published early for conference participants by SABCS. Arvinas’ stock price has since fallen by 18% over the first two days of the holiday-shortened week.
An experimental vaccine provided broad protection against all 20 known influenza A and B virus subtypes in initial tests in mice and ferrets, potentially opening a pathway to a universal flu shot that might help prevent future pandemics, according to a U.S. study published on Thursday.
Recent uptake of COVID-19 vaccine booster doses in the European Union has been “rather disappointing,” an official said on Thursday, amid concerns that protection against severe cases of the disease could weaken during the winter.
Pfizer Inc. and its German partner BioNTech SE said their Omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the emerging subvariant BQ.1.1 than its original vaccine.
Pharmaceutical companies could be made to disclose prices and deals agreed for any products they make to fight future global health emergencies, under new rules that would govern a World Health Organization-backed pandemic accord reviewed by Reuters.
The head of the panel of 18 appointees, known as STIKO, said there was no clear case for broad use, citing a lack of data to rule out any rare side effects and no signs of the infection causing severe illness in otherwise healthy children.